Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
558.37B
Market cap558.37B
Price-Earnings ratio
26.15
Price-Earnings ratio26.15
Dividend yield
2.30%
Dividend yield2.30%
Average volume
8.37M
Average volume8.37M
High today
$229.99
High today$229.99
Low today
$227.02
Low today$227.02
Open price
$229.04
Open price$229.04
Volume
6.07M
Volume6.07M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$146.12
52 Week low$146.12

Stock Snapshot

With a market cap of 558.37B, Johnson & Johnson(JNJ) trades at $227.35. The stock has a price-to-earnings ratio of 26.15 and currently yields dividends of 2.3%.

On 2026-04-25, Johnson & Johnson(JNJ) stock traded between a low of $227.02 and a high of $229.99. Shares are currently priced at $227.35, which is +0.1% above the low and -1.1% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 6.07M, against a daily average of 8.37M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $251.71 and a 52-week low of $146.12.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $251.71 and a 52-week low of $146.12.

JNJ News

Simply Wall St 1d
Did New IMAAVY Data in Myasthenia Gravis Just Shift Johnson & Johnson's Investment Narrative?

Earlier this week, Johnson & Johnson reported long-term Phase 3 Vivacity-MG3 and open-label extension data for IMAAVY (nipocalimab-aahu) in generalized myasthen...

Did New IMAAVY Data in Myasthenia Gravis Just Shift Johnson & Johnson's Investment Narrative?
24/7 Wall St. 2d
These 5 Stocks Pay You Even When You’re Sleeping

These 5 Stocks Pay You Even When You’re Sleeping By Vandita Jadeja Published Apr 23, 4:04PM EDT Quick Read Johnson & Johnson (JNJ) raised its dividend for 64...

These 5 Stocks Pay You Even When You’re Sleeping
Seeking Alpha 2d
JNJ set to snap six straight sessions of losses

Johnson & Johnson (JNJ) shares set to snap six straight sessions of losses on Thursday, as the stock rose 1.9% to $230.42 in afternoon trading. The New Brunswi...

JNJ set to snap six straight sessions of losses

Analyst ratings

59%

of 29 ratings
Buy
58.6%
Hold
34.5%
Sell
6.9%

More JNJ News

Simply Wall St 2d
IMAAVY Data And AI MedTech Launch Test Johnson & Johnson Dividend Story

Johnson & Johnson (NYSE:JNJ) reported new long-term clinical data for IMAAVY (nipocalimab-aahu) in generalized myasthenia gravis from the Phase 3 Vivacity-MG3 t...

IMAAVY Data And AI MedTech Launch Test Johnson & Johnson Dividend Story
Nasdaq 3d
Small Cap or Megacap: Which Healthcare Stock Is Right for You?

Key Points Larger companies offer more stability but may offer less stock price appreciation. Smaller companies face more risk but may offer more upside than...

Small Cap or Megacap: Which Healthcare Stock Is Right for You?
TipRanks 3d
Johnson & Johnson reports new data from Phase 3 Vivacity-MG3 study

Johnson & Johnson announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension, or OLE, in a broad population of antibody-positive, o...

Nasdaq 3d
J&J Innovative Medicine Drives Q1 Strength: Key to Long-Term Growth?

Johnson & Johnson JNJ, via its Innovative Medicine segment, markets a broad portfolio of blockbuster therapies across key areas including neuroscience, cardiova...

J&J Innovative Medicine Drives Q1 Strength: Key to Long-Term Growth?
TipRanks 3d
MeiraGTx price target raised to $30 from $26 at Piper Sandler

Piper Sandler raised the firm’s price target on MeiraGTx (MGTX) to $30 from $26 and keeps an Overweight rating on the shares following the company’s long-term d...

Simply Wall St 4d
A Look At Johnson & Johnson Valuation After Recent Share Price Weakness

Johnson & Johnson (JNJ) stock is drawing attention after recent trading left shares around $226.16, with a 1 day return of about a 2% decline and a past week mo...

A Look At Johnson & Johnson Valuation After Recent Share Price Weakness
24/7 Wall St. 4d
GDV's 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn By David Beren Published Apr 21, 3:34PM EDT Quick Read Gabelli Dividend & Income Trust (GDV) t...

GDV's 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.